五肽 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
Weight gain is also less of a concern with ziprasidone compared to other atypical antipsychotics. In fact, in a trial of long term therapy with ziprasidone, overweight patients (BMI > 27) actually had a mean weight loss overall. According to the manufacturer insert, ziprasidone caused an average weight gain of 2.2 kg (4.8 lbs), which is significantly lower than other atypical antipsychotics, making this medication better for patients that are concerned about their weight. In December 2014, the FDA warned that ziprasidone could cause a potentially fatal skin reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), although this was believed to occur only rarely.
=== Child soldiers and human shields === Houthis have been accused of violations of international humanitarian law, such as using child soldiers, shelling civilian areas, forced evacuations and executions. According to Human Rights Watch, Houthis intensified their recruitment of children in 2015. UNICEF mentioned that children with the Houthis and other armed groups in Yemen comprise up to a third of all fighters in Yemen. Human Rights Watch has further accused Houthi forces of using landmines in Yemen's third-largest city of Taizz, which has caused many civilian casualties and prevented the return of families displaced by the fighting. HRW has also accused the Houthis of interfering with the work of Yemen's human rights advocates and organizations. In 2009, HRW researcher Christoph Wilcke said that although the Republic of Yemen Government accused the Houthis of using civilians as human shields, HRW did not have enough evidence to conclude that the Houthis were intentionally doing so. Nonetheless, Wilcke stated that there may have been cases in which HRW was unable to document. Akram Al Walidi, one of four journalists detained by the Houthis on spying charges and then released in April 2023 as part of a prisoner exchange deal between the former and the internationally recognized government of Yemen, said he felt like the four were human shields after the Houthis moved them to one of their military camps at Sanaa in October 2020 since it was an expected target of Saudi airstrikes.
Certain functions necessary to the trial, such as monitoring and lab work, may be managed by an outsourced partner, such as a contract research organization or a central laboratory. Only 10 percent of all drugs started in human clinical trials become approved drugs. Data collection is a key activity within clinical trials and digital data collection tools can assist greatly in this effort.
Sources: en.wikipedia.org
=== Workforce and operational practices === In 2022, Eucalyptus had to cut 20% of its staff from across their brands after an investment firm pulled out of its decision to loan the company money. The investment firm was not named however the layoffs affected 50 to 60 people across multiple brands of the company. Comparable overseas start-ups, such as Ro (company) and Hims & Hers Health have faced similar struggles. In 2026, four current and former medical assistants from the Philippines spoke anonymously against Eucalyptus and their "impossible" benchmarks that were raised in 2025. It is alleged that Eucalyptus raised the number of queries that each assistant should process to more than 65 a day, with some employees assigned up to 80 new tickets. Failing to meet these metrics leads to escalation from management with fear of termination. The pressure aligns with Eucalyptus' growth however has led to increased employee turnover and dependence on AI.
=== Asbestos === While Grace no longer makes asbestos or related products, at the time of its bankruptcy in 2001, it faced over 65,000 asbestos-related personal injury lawsuits involving over 129,000 claims. On April 2, 2001, Grace and its subsidiaries in the United States filed voluntary petitions for Chapter 11 Bankruptcy reorganization in the Bankruptcy Court for the District of Delaware. The company was trying to find a resolution through federal court-supervised reorganization in response to the quickly growing number of asbestos-related bodily injury claims. On September 19, 2008, Grace filed a revised plan of reorganization to the same court, jointly with the asbestos injury claimants. In January 2011, the court issued an order in favor of the new plan and in January 2012, the court denied all appeals and affirmed the plan. After a motion for reconsideration, the plan was reaffirmed on June 11, 2012. On February 3, 2014, Grace emerged from the asbestos-related Chapter 11 bankruptcy, which took more than 12 years. Under the plan of reorganization approved by the court, all parties filings the asbestos-related claims were to direct their inquiry to either an asbestos personal injury trust or a separate asbestos property damage trust.
=== Federal government === President Luiz Inácio Lula da Silva Vice President Geraldo Alckmin President of the Chamber of Deputies Hugo Motta President of the Federal Senate Davi Alcolumbre President of the Supreme Federal Court Edson Fachin
== Structural studies == As of late 2007, 13 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1AY4, PDB: 1AY5, PDB: 1AY8, PDB: 2AY1, PDB: 2AY2, PDB: 2AY3, PDB: 2AY4, PDB: 2AY5, PDB: 2AY6, PDB: 2AY7, PDB: 2AY8, PDB: 2AY9, and PDB: 3TAT.
Sources: en.wikipedia.org
Ritanserin, also known by its developmental code name R-55667, is a serotonin receptor antagonist which was under development for the treatment of anxiety disorders and major depressive disorder but was never marketed. It was also investigated for treatment of insomnia, especially to enhance sleep quality by significantly increasing slow wave sleep by virtue of potent and concomitant serotonin 5-HT2A and 5-HT2C receptor antagonism. The drug is taken orally.
=== Film adaptation === In February 2013, Valve president Gabe Newell and film director J. J. Abrams announced that they were to collaborate on a film adaptation of the Portal series. In 2016, Abrams stated that he still has plans to direct these films in the future, with both films in the writing stage. Abrams confirmed in May 2021 that the film adaptation was still in the works as they were still working on a script for the film from Warner Bros. Pictures. In 2026, Kane Parsons also expressed interest in directing a Portal film.
==== Yopo ==== Snuff trays and tubes similar to those commonly used for yopo were found in the central Peruvian coast dating back to 1200 BC, suggesting that insufflation of Anadenanthera beans is a more recent method of use. Archaeological evidence of insufflation use within the period 500-1000 AD, in northern Chile, has been reported.
Unlike folinic acid, it may be used in MTFHR deficiency and MTHFS deficiency: 5-MTHF is the directly usable form of folate in methoinine metabolism, in contrast to folinic acid which needs to be converted to 5-MTHF by these enzymes. Secondary CFD could be treated by non-folate drugs, depending on the precise cause. For example, serine deficiency can be helped by direct supplementation of serine and glycine: this helps with seizure control but does little for psychomotor development. Folic acid (FA), the oxidized form commonly found in diet and ordinary supplements, is not suitable for most forms of CFD and may worsen it. "Transport of folate compounds from the intestine to the brain and competitive inhibition of 5-MTHF transport by FA. Conversion of FA to 5-MTHF is limited in the intestine and is mainly handled by DHFR in the liver, although its enzymatic activity is low in humans. In contrast, folinic acid is efficiently metabolized to 5-MTHF in the intestine and liver. When an excess amount of FA is taken, it cannot be fully reduced by DHFR in the liver and unmetabolized FA appears in the plasma. Because FA has higher affinity to FR1 expressed at the choroid plexus than 5-MTHF, it can act as a competitive inhibitor against 5-MTHF transport from the plasma to the CSF. In addition, FA cannot be metabolized to 5-MTHF efficiently in the brain with extremely low DHFR activity. Thus, excess FA intake may lead to a less effective supply of 5-MTHF to the brain compared with that of folinic acid supplementation."
=== Submachine guns === Sten – Used very early on, replaced by the early 1960s. Suppressed versions remained in use into the late 1960s. Lanchester submachine gun - Royal Navy issue into the 1970s Sterling submachine gun – Main submachine gun, adopted in 1953. Suppressed L34A1 version adopted in 1967. MAC-10 - Special forces issue until the early 1980s, also used by 14 Intelligence Company. 9x19mm model. Heckler & Koch MP5 - Special forces issue from the late 1970s; MP5A3, MP5SD3, and MP5K. MP5K also used by 14 Intelligence Company.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.